Abstract: Self-assembling peptides or self-assembling peptidomimetics (“SAP”) can treat inflammation or inflammatory diseases, or reduce one or more symptoms of diseases and disorders associated with undesirable inflammation. Topical and injectable compositions of SAP for local administration to a site of inflammation for reduction or prevention of symptoms of inflammatory diseases and disorders are described. The compositions include one or more SAP in an amount and concentration effective to reduce or prevent one or more symptoms of undesirable inflammation. The SAP can assemble prior to or after the composition is administered. The SAP form a structure within or at the surface of the body that prevents and/or reduces symptoms associated with inflammation and other dysregulated immune processes. The peptides can assemble upon contact with bodily fluids (e.g., synovial fluid), or can be contacted with ionic solutions to initiate assembly.

Abstract: Compositions that include nanoscale structured materials or precursors thereof (e.g., self: assembling peptides) are described. The compositions can include other substances (e.g., a vasoconstrictor). Also described are methods for using the compositions to promote hemostasis, to protect the skin or wounds from contamination, to decontaiminate a site upon removal of previously applied compositions that provided a protective coating, and to inhibit the movement of bodily substances other than blood. The compositions are also useful in isolating tissue, removing tissue, preserving tissue (for, e.g., subsequent transplantation or reattachment), and as bulking, stabilizing or hydrating agents. Medical devices that include the compositions (e.g., a stent or catheter), bandages or other wound dressings, sutures, and kits that include the compositions are also described.

Abstract: Self-assembling peptides or self-assembling peptidomimetics (“SAP”) can treat or alleviate disease, disorder, injury or one or more symptoms of diseases or disorders of the eye, including ocular inflammation, dry eye, corneal erosion, retinal detachment, and other problems where the barrier formed by the SAP provides protection and aids healing. SAP topical or injectable compositions of SAP for local administration to the eye include SAP in an amount and concentration effective to provide an SAP structure on or within the eye or a compartment or structure thereof. The SAP can be assembled prior to or after the composition is administration. SAP can also be used as coatings for contact lens, intraocular lens, and wound healing devices, to enhance healing and decrease inflammation.

Abstract: Compositions containing self-assembling peptides and/or self-assembling peptidomimetics (“self-assembling peptides”) can be used to create a long-lasting “lift” or means of elevating tissue to be resected, dissected, manipulated or repaired, as a bulking agent, or as a tissue forming matrix by injection of a solution that forms a solid gel in situ, which is stable for a prolonged period of time from days to a month, is hemostatic, and may prevent adhesions. These self-assembling peptides and methods of use thereof enable better separation of tissues and visualization of margins, more durable and robust lifts, less need for frequent injections that carry risk of undesired perforation, and simultaneous management of adverse effects, such as bleeding, leaking, inflammation and iatrogenic injury during endoscopic, laparoscopic or other minimally invasive, or open surgical procedures in and/or on the body.

Abstract: Meshes for use to control the movement of bodily fluids, such as blood, are described herein. The mesh can be partially or completely biodegradable or non-biodegradable. In one embodiment, the mesh is formed from one or more self-assembling peptides. The peptides can be in the form of fibers, such as nanofibers. The peptides can be assembled prior to formation of the mesh or after the mesh has been formed but before it is applied. Alternatively, the mesh can be prepared from unassembled peptides, which assemble at the time of application. The peptides can assemble upon contact with bodily fluids (e.g., blood) or can be contacted with an ionic solution to initiate assembly.

Abstract: A method has been developed of preventing or limiting formation of adhesions by administering to a site in need thereof, in the absence of or after bleeding or leakage of fluid has been substantially stopped, a self-assembling material which forms a barrier to formation of adhesions. In certain embodiments, the self assembling materials are peptidomimetics, nucleotidomimetics, di- and triblock copolymers, N-alkylacrylamides, or dendrimers. These materials are also useful in a method for regeneration or repair of tissue or cells forming tissue.

Abstract: Self-assembling peptides or self-assembling peptidomimetics (“SAP”) can treat or alleviate disease, disorder, injury or one or more symptoms of diseases or disorders of the eye, including ocular inflammation, dry eye, corneal erosion, retinal detachment, and other problems where the barrier formed by the SAP provides protection and aids healing. SAP topical or injectable compositions of SAP for local administration to the eye include SAP in an amount and concentration effective to provide an SAP structure on or within the eye or a compartment or structure thereof. The SAP can be assembled prior to or after the composition is administration. SAP can also be used as coatings for contact lens, intraocular lens, and wound healing devices, to enhance healing and decrease inflammation.

Abstract: Self-assembling peptides or self-assembling peptidomimetics (“SAP”) can treat inflammation or inflammatory diseases, or reduce one or more symptoms of diseases and disorders associated with undesirable inflammation. Topical and injectable compositions of SAP for local administration to a site of inflammation for reduction or prevention of symptoms of inflammatory diseases and disorders are described. The compositions include one or more SAP in an amount and concentration effective to reduce or prevent one or more symptoms of undesirable inflammation. The SAP can assemble prior to or after the composition is administered. The SAP form a structure within or at the surface of the body that prevents and/or reduces symptoms associated with inflammation and other dysregulated immune processes. The peptides can assemble upon contact with bodily fluids (e.g., synovial fluid), or can be contacted with ionic solutions to initiate assembly.

Abstract: Meshes for use to control the movement of bodily fluids, such as blood, are described herein. The mesh can be partially or completely biodegradable or non-biodegradable. In one embodiment, the mesh is formed from one or more self-assembling peptides. The peptides can be in the form of fibers, such as nanofibers. The peptides can be assembled prior to formation of the mesh or after the mesh has been formed but before it is applied. Alternatively, the mesh can be prepared from unassembled peptides, which assemble at the time of application. The peptides can assemble upon contact with bodily fluids (e.g., blood) or can be contacted with an ionic solution to initiate assembly.

Abstract: Meshes for use to control the movement of bodily fluids, such as blood, are described herein. The mesh can be partially or completely biodegradable or non-biodegradable. In one embodiment, the mesh is formed from one or more self-assembling peptides. The peptides can be in the form of fibers, such as nanofibers. The peptides can be assembled prior to formation of the mesh or after the mesh has been formed but before it is applied. Alternatively, the mesh can be prepared from unassembled peptides, which assemble at the time of application. The peptides can assemble upon contact with bodily fluids (e.g., blood) or can be contacted with an ionic solution to initiate assembly.

Abstract: Compositions which self-assemble under physiological conditions are formulated for application to wounds. The formulations include a pharmaceutically acceptable carrier or are provided as part of a medical device or coating. The formulations may also include other therapeutic, prophylactic or diagnostic agents. The formulation can be administered for treatment of one or more disorders or conditions. For example, the formulation may be applied to repair an injury or during surgery of the lung, eye or dura, or following an epidural or spinal tap, to stop leakage of blood, interstitial fluid, or cerebrospinal fluid. The formulation may be administered to a burn or ulcer. In one embodiment, the formulation is provided as a dry or lyophilized powder. In another embodiment, the material is provided in water. In another embodiment, the material is provided in combination with an oil and forms a laminate.

Abstract: Meshes for use to control the movement of bodily fluids, such as blood, are described herein. The mesh can be partially or completely biodegradable or non-biodegradable. In one embodiment, the mesh is formed from one or more self-assembling peptides. The peptides can be in the form of fibers, such as nanofibers. The peptides can be assembled prior to formation of the mesh or after the mesh has been formed but before it is applied. Alternatively, the mesh can be prepared from unassembled peptides, which assemble at the time of application. The peptides can assemble upon contact with bodily fluids (e.g., blood) or can be contacted with an ionic solution to initiate assembly.

Abstract: A method has been developed of preventing or limiting formation of adhesions by administering to a site in need thereof, in the absence of or after bleeding or leakage of fluid has been substantially stopped, a self-assembling material which forms a barrier to formation of adhesions. In certain embodiments, the self assembling materials are peptidomimetics, nucleotidomimetics, di- and triblock copolymers, N-alkylacrylamides, or dendimers. These materials are also useful in a method for regeneration or repair of tissue or cells forming tissue.

Abstract: Meshes for use to control the movement of bodily fluids, such as blood, are described herein. The mesh can be partially or completely biodegradable or non-biodegradable. In one embodiment, the mesh is formed from one or more self-assembling peptides. The peptides can be in the form of fibers, such as nanofibers. The peptides can be assembled prior to formation of the mesh or after the mesh has been formed but before it is applied. Alternatively, the mesh can be prepared from unassembled peptides, which assemble at the time of application. The peptides can assemble upon contact with bodily fluids (e.g., blood) or can be contacted with an ionic solution to initiate assembly.

Abstract: A method has been developed of preventing or limiting formation of adhesions by administering to a site in need thereof, in the absence of or after bleeding or leakage of fluid has been substantially stopped, a self-assembling material which forms a barrier to formation of adhesions. In certain embodiments, the self assembling materials are peptidomimetics, nucleotidomimetics, di- and triblock copolymers, N-alkylacrylamides, or dendimers. These materials are also useful in a method for regeneration or repair of tissue or cells forming tissue.

Abstract: Compositions which self-assemble under physiological conditions are formulated for application to wounds. The formulations include a pharmaceutically acceptable carrier or are provided as part of a medical device or coating. The formulations may also include other therapeutic, prophylactic or diagnostic agents. The formulation can be administered as appropriate for treatment of one or more disorders or conditions. For example, the formulation may be applied to repair an injury or during surgery of the lung, eye or dura, or following an epidural or spinal tap, to stop leakage of blood, interstitial fluid, or cerebrospinal fluid. The formulation may be administered to a burn or ulcer. The formulation may be dispersed in a suture or adhesive for administration at the time of or as released following suturing or gluing of a wound, thereby limiting bleeding, loss of tissue fluids, or other fluids such as those produced by parenchymal tissues such as the liver, pancreas, and gastrointestinal tract.

Abstract: Method are described for inhibiting movement of a bodily fluid and/or contaminants on or in an animal comprising administering to the animal self-assembling peptidomimetics, including ?-peptides, ?-peptides, ?-peptides, and/or ?-peptides.

Abstract: Self assembling peptides and peptidomimetics can be utilized for the treatment and support of disorders associated with leaky or damaged tight junction and weak, diseased, or injured extracellular matrix. The self-assembling materials generally have alternating hydrophilic or hydrophobic residues or hydrophobic and/or hydrophilic sections which allow the material to react or interact with the glycoproteins found in the ECM. Diseases in which treatment with these materials applied to or near the site in need of treatment include diabetic retinopathy, sepsis, burns, and certain neurodegenerative diseases such as Parkinson's and Alzheimer's. The formulations can be administered by injection, spraying, topically or by catheter or via a wound dressing or other material to which it is applied and then applied to the site in need of treatment.

Abstract: Meshes for use to control the movement of bodily fluids, such as blood, are described herein. The mesh can be partially or completely biodegradable or non-biodegradable. In one embodiment, the mesh is formed from one or more self-assembling peptides. The peptides can be in the form of fibers, such as nanofibers. The peptides can be assembled prior to formation of the mesh or after the mesh has been formed but before it is applied. Alternatively, the mesh can be prepared from unassembled peptides, which assemble at the time of application. The peptides can assemble upon contact with bodily fluids (e.g., blood) or can be contacted with an ionic solution to initiate assembly.

Abstract: Compositions that include nanoscale structured materials or precursors thereof (e.g., self: assembling peptides) are described. The compositions can include other substances (e.g., a vasoconstrictor). Also described are methods for using the compositions to promote hemostasis, to protect the skin or wounds from contamination, to decontaiminate a site upon removal of previously applied compositions that provided a protective coating, and to inhibit the movement of bodily substances other than blood. The compositions are also useful in isolating tissue, removing tissue, preserving tissue (for, e.g., subsequent transplantation or reattachment), and as bulking, stabilizing or hydrating agents. Medical devices that include the compositions (e.g., a stent or catheter), bandages or other wound dressings, sutures, and kits that include the compositions are also described.